Bnip3 in mitophagy: Novel insights and potential therapeutic target for diseases of secondary mitochondrial dysfunction

作     者：Gao, Anbo Jiang, Jinyong Xie, Feng Chen, Linxi 

作者机构：Univ South China Hunan Prov Cooperat Innovat Ctr Mol Target New Dr Inst Pharm & Pharmacol Learning Key Lab Pharmacoprote Hengyang 421001 Peoples R China Univ South China Hengyang Med Sch Hengyang 421001 Peoples R China Nanshan Dist Matern & Child Healthcare Hosp Shenz Shenzhen 518052 Peoples R China 

出 版 物：《CLINICA CHIMICA ACTA》 (临床化学学报)

年 卷 期：2020年第506卷

页      面：72-83页

核心收录：

学科分类：1006[医学-中西医结合] 1002[医学-临床医学] 1010[医学-医学技术（可授医学、理学学位）] 10[医学] 100602[医学-中西医结合临床] 

基　　金：National Natural Science Foundation of China 

主　　题：Bnip3 Mitophagy Cardiac hypertrophy Hepatocellular carcinoma Non-alcoholic fatty liver disease 

摘      要：The present review is a summary of the recent literature concerning Bnip3 expression, function, and regulation, along with its implications in mitochondrial dysfunction, disorders of mitophagy homeostasis, and development of diseases of secondary mitochondrial dysfunction. As a member of the Bcl-2 family of cell death-regulating factors, Bnip3 mediates mPTP opening, mitochondrial potential, oxidative stress, calcium overload, mitochondrial respiratory collapse, and ATP shortage of mitochondria from multiple cells. Recent studies have discovered that Bnip3 regulates mitochondrial dysfunction, mitochondrial fragmentation, mitophagy, cell apoptosis, and the development of lipid disorder diseases via numerous cellular signaling pathways. In addition, Bnip3 promotes the development of cardiac hypertrophy by mediating inflammatory response or the related signaling pathways of cardiomyocytes and is also responsible for raising abnormal mitophagy and apoptosis progression through multiple molecular signaling pathways, inducing the pathogenesis and progress of hepatocellular carcinoma (HCC). Different molecules regulate Bnip3 expression at both the transcriptional and post-transcriptional level, leading to mitochondrial dysfunction and unbalance of mitophagy in hepatocytes, which promotes the development of non-alcoholic fatty liver disease (NAFLD). Thus, Bnip3 plays an important role in mitochondrial dysfunction and mitophagy homeostasis and has emerged as a promising therapeutic target for diseases of secondary mitochondrial dysfunction.